DOCSLIB.ORG

Cgmp Signaling, Phosphodiesterases and Major Depressive Disorder

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cgmp Signaling, Phosphodiesterases and Major Depressive Disorder Current Neuropharmacology, 2011, 9, 715-727 715 cGMP Signaling, Phosphodiesterases and Major Depressive Disorder Gillian W. Reierson1, Shuyu Guo2, Claudio Mastronardi2, Julio Licinio2 and Ma-Li Wong2,* 1University of Miami Miller School of Medicine, Miami, FL, USA; 2Department of Translational Medicine, John Curtin School of Medical Research, Australian National University, Acton, ACT, Australia Abstract: Deficits in neuroplasticity are hypothesized to underlie the pathophysiology of major depressive disorder (MDD): the effectiveness of antidepressants is thought to be related to the normalization of disrupted synaptic trans- mission and neurogenesis. The cyclic adenosine monophosphate (cAMP) signaling cascade has received considerable attention for its role in neuroplasticity and MDD. However components of a closely related pathway, the cyclic guanosine monophosphate (cGMP) have been studied with much lower intensity, even though this signaling transduction cascade is also expressed in the brain and the activity of this pathway has been implicated in learning and memory processes. Cyclic GMP acts as a second messenger; it amplifies signals received at postsynaptic receptors and activates downstream effector molecules resulting in gene expression changes and neuronal responses. Phosphodiesterase (PDE) enzymes degrade cGMP into 5’GMP and therefore they are involved in the regulation of intracellular levels of cGMP. Here we review a growing body of evidence suggesting that the cGMP signaling cascade warrants further investigation for its involvement in MDD and antidepressant action. Keywords: Major Depression, cyclic guanosine monophosphate, neurogenesis, neuroplasticity, phophodiesterases, cyclases, antidepressants, pharmacology. 1. INTRODUCTION has received little attention in the biology of MDD and antidepressant action. The cGMP signaling cascade consists Major depressive disorder (MDD) is a chronic and highly of a number of different elements that can regulate cGMP disabling condition. It is the most common mood disorder: levels and influence downstream cellular responses. Fig. (1) up to 17% of the population suffers from this condition at depicts the presynaptic and postsynaptic elements of the some point during their lifetimes. While antidepressants have cGMP signaling pathway in the central nervous system; been shown to be effective in treating the symptoms of MDD these elements are expressed in the hippocampus, a brain in 60-70% of patients, 30-40% of patients do not respond to region that has been implicated in MDD [8, 9]. Pharma- pharmacotherapy [1, 2]. Furthermore, antidepressants must cotherapy targeting different elements of the cGMP pathway be taken chronically for several weeks before treatment re- is currently available; this class of drugs includes phosphodi- sponse is achieved and it is still unclear what are the mecha- esterase inhibitors, which increase cGMP signaling. In this nisms by which these drugs relieve the clinical symptoms of review, we summarize the evidence that supports the role of MDD. Evidence from clinical and preclinical research accu- cGMP signaling in neuroplasticity and in the pathophysiology mulated in recent years support the concept that aberrant of MDD and antidepressant treatment response, with a neuroplasticity, including functional synaptic plasticity and specific focus on the role of phosphodiesterases (PDEs). structural plasticity, in the hippocampus and prefrontal cortex, might underlie MDD [3, 4]. Intracellular cyclic adenosine 2. cGMP SIGNALING COMPONENTS AND THEIR monophosphate (cAMP) signaling activated by brain-derived DISTRIBUTION IN THE BRAIN neurotrophic factor (BDNF) has been shown to be a pivotal player in neuroplasticity and MDD; moreover, studies 2.1. cGMP Synthesis: pGC and sGC have demonstrated that treatment with antidepressants The synthetic enzyme guanylate/guanylyl cyclase (GC) can alter the expression of components of this signaling converts guanosine triphosphate (GTP) to 3’-5’-cyclic pathway in rodents [5-7]. Unfortunately, earlier findings guanosine monophosphate to produce the second messenger have been inconsistently replicated making it premature to molecule known as cGMP. The production of cGMP by GC conceptualize translational strategies for new antidepressant can occur in two different ways: 1) following activation of pharmacotherapy targeting the cAMP signaling. The cyclic membrane bound guanylate cyclase (particulate GC or pGC) guanosine monophosphate (cGMP) signaling pathway is [10, 11] and 2) following activation of soluble guanylate an intracellular nucleotide cascade that is also involved in cyclase (sGC, also called NO receptors) in the cytoplasm by neuroplasticity. It is closely related to cAMP signaling, but it the diffusible second messenger molecule, nitric oxide (NO) [12, 13]. *Address correspondence to this author at Building 131, Garran Road, John Curtin School of Medical Research, The Australian National University Particulate GC is composed of two subfamilies: the pep- Canberra, ACT, Australia; Tel: +61 2 6125 8557; Fax: +61 2 6125 2337; tide hormone receptor subfamily, which binds natriuretic 2+ E-mail: [email protected] peptides, and the Ca -modulated ROS-GC (rod outer 1570-159X/11 $58.00+.00 ©2011 Bentham Science Publishers 716 Current Neuropharmacology, 2011, Vol. 9, No. 4 Reierson et al. cAMP PDE sGC cGMP PKGI VASP Glutamate CNG CNG AMPA receptor insertion Synaptic protein NO Neurogensis accumulation AMPAR AMPAR NMDAR NMDAR AMPAR AMPAR PI3K/Akt/Gsk3 Ca2+ CaMK L-Arginine nNOs L-Citrulline NO O2 PKGII sGC cGMP PKGI VASP PKG Transcription apparatus CREB Genetic Changes Nucleus Fig. (1). The cGMP signaling pathway. Presynaptic (top) and postsynaptic (bottom) elements of the cGMP signaling cascade are represented. AMPAR = 2-amino-3-(5-methyl-3-oxo-1,2-oxal-4-yl)propanoic acid receptor; CaMK = calcium-calmodium-dependent kinase; cAMP = cyclic adenosine monophosphate; cGMP = cyclic guanosine monophosphate; CNG = cyclic nucleotide gated channels; NO = nitric oxide; nNO = neuronal NO; PDE = phosphodiesterase; PI3K/AKT/Gsk3 = phosphoinositide 3-kinase/protein kinase B (aka AKT)/glycogen synthase kinase 3; PKGI = cGMP dependent protein kinase I; PKGII = cGMP dependent protein kinase II; sGC = soluble guanylate cyclase; VASP = vasodilator-stimulated phosphoprotein. cGMP Signaling, Phosphodiesterases and Major Depression Disorder Current Neuropharmacology, 2011, Vol. 9, No. 4 717 segment-derived guanylate cyclase) subfamily, which is PDE9) and dual substrate PDEs (PDE1, PDE2, PDE3, linked with the senses of vision, olfaction and taste, and PDE10, and PDE11). light-regulated pinealocytes [1, 14-16]. The isoforms of pGC All cGMP specific PDEs are expressed in the brain. In expressed in the brain include guanylate cyclase A/natriuretic peptide receptor 1 (GC-A/Npr1), guanylate cyclase B/natriuretic the rodent brain, PDE5A mRNA expression has been re- ported in the purkinje cells of the cerebellum; strong staining peptide receptor 2 (GC-B/Npr2), guanylate cyclase 2D (GC- has also been observed in scattered cells in the hippocampus, D/GUCY2D); while two eye-specific GC have been identi- including pyramidal cells of CA1, CA2 and CA3, as well as fied in mammals (designed GC-E and GC-F or RetGC-1 and in the dentate gyrus [33]. PDE6 was initially thought to be RetGC-2 in humans) [17-19]. GC-A/Npr1 is activated by limited to the retina; however, PDE6B mRNA expression atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) and the mRNA is expressed in the subfornical organ, has also been reported in mouse hippocampus [34]. CNS expression of the PDE9A mRNA in the rodent brain has medial habenula, cerebellum and olfactory bulb [20, 21]. been reported in the purkinje cells and granule cells of the GC-B/Npr2 is activated by natriuretic peptide type C (CNP) cerebellum, olfactory bulb and tubercle, caudate putamen, and the mRNA is expressed in the pineal gland, cerebellum, and CA1 and dentate gyrus areas of the hippocampus [35- cortex, hippocampus, hypothalamus, olfactory bulb, neural 37]. In the human brain, PDE9 mRNA expression has been lobe of the pituitary gland, and thalamus [21, 22]. GC-D is expressed in the olfactory bulb in rodents, but it is a reported in the insular and visual cortices as well as in the CA1, CA2 and CA3 subfields, and dentate gyrus of the hip- pseudogene in humans [23]. pocampal formation [38]. Soluble GC exists as a heterodimer composed of differ- All dual substrate cGMP are also expressed in the brain. ent combinations of subunits (1 or 2) and subunits In rodents, in situ hybridization and immunohistochemistry (1 or 2); all sGC subunits mRNAs are expressed in the studies demonstrated that the PDE1A isoform is expressed in brain with the exception of the 2 subunit mRNAs [24]. the following brain areas: cerebral cortex, pyramidal cells of Both 1 and 2 sGC subunits mRNAs are expressed in the the hippocampus, and striatum [39, 40]. PDE1B is also ex- cerebral cortex and olfactory bulb; 1 is also expressed in pressed in several brain areas including the caudate-putamen, striatum and pallidum and 2 is also expressed in hippocam- nucleus accumbens, dentate gyrus of hippocampus, olfactory pus and medulla [21]. The 1 sGC subunit mRNA is tubercle, medial thalamic nuclei, and brainstem [39, 40]. expressed throughout the brain, with predominant expression PDE1C mRNA is expressed in the granule cells of the cere- in the cerebral cortex, hippocampus, lateral septal complex, olfactory bulb, and striatum [21, 24]. In the
Load more

Recommended publications
  • WO 2017/048702 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2017/048702 A l 2 3 March 2017 (23.03.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 487/04 (2006.01) A61P 35/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/519 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 16/05 1490 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 13 September 2016 (13.09.201 6) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/218,493 14 September 2015 (14.09.2015) US (84) Designated States (unless otherwise indicated, for every 62/218,486 14 September 2015 (14.09.2015) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: INFINITY PHARMACEUTICALS, INC.
    [Show full text]
  • Development and Validation of a UHPLC-UV Method for The
    Development and validation of a UHPLC-UV method for the detection and quantification of erectile dysfunction drugs and some of their analogues found in counterfeit medicines. Pierre-Yves Sacré a,b, Eric Deconinck a, Patrice Chiap c, Jacques Crommen b, François Mansion b, Eric Rozet d, Patricia Courselle a, Jacques O. De Beer a,* a Laboratory of Drug Analysis, Scientific Institute of Public Health, Brussels, Belgium b Department of Analytical Pharmaceutical Chemistry, Institute of Pharmacy, University of Liège, Liège, Belgium. c Advanced Technology Corporation (A.T.C.), University Hospital of Liège, Liège, Belgium d Department of Analytical Chemistry, Institute of Pharmacy, University of Liège, Liège, Belgium. Abstract Pharmaceutical counterfeiting is a permanently growing problem. Control laboratories are constantly analysing counterfeit medicines. In industrialised countries, one of the main counterfeited class of medicines are erectile dysfunction drugs. This paper describes the development and validation of a fast method to detect and quantify the three authorised phosphodiesterase type 5 inhibitors and five analogues. The method is based on the use of a sub-2 microns polar-embedded column with a gradient using acetonitrile as organic modifier and 10 mM ammonium formate buffer (pH 3.5) as aqueous component of the mobile phase. The separation was achieved in less than 4.5 min. The method has also been compared to the registered HPLC method for the assay of Viagra ® which was considered as the reference method. The method is also compatible with on-line coupling mass spectrometry and will significantly reduce analysis times and solvent consumption. Keywords: Phosphodiesterase type 5 inhibitors; UHPLC; method validation, analogues, counterfeit drugs, accuracy profiles.
    [Show full text]
  • [3H]-Piclamilast and [3H]-Rolipram
    JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 JPET FastThis articleForward. has not Published been copyedited on and January formatted. 24,The final2003 version as DOI:10.1124/jpet.102.047407 may differ from this version. Inhibitor Binding to Type 4 Phosphodiesterase (PDE4) Assessed Using [3H]-Piclamilast and [3H]-Rolipram Yu Zhao, Han-Ting Zhang, and James M. O’Donnell Department of Pharmacology University of Tennessee Health Science Center Downloaded from Memphis, Tennessee jpet.aspetjournals.org at ASPET Journals on September 27, 2021 1 Copyright 2003 by the American Society for Pharmacology and Experimental Therapeutics. JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted. The final version may differ from this version. Running title: Inhibitor binding to PDE4 Correspondence should be addressed to: James M. O’Donnell, Ph.D. Department of Pharmacology University of Tennessee Health Science Center 874 Union Avenue Downloaded from Memphis, TN 38163 jpet.aspetjournals.org Phone: 901-448-3621 Fax: 901-448-3849 Email: [email protected] at ASPET Journals on September 27, 2021 Number of text page: 31 Number of tables: 3 Number of figures: 7 Number of references: 50 Number of words: Abstract (241); Introduction (716); Discussion (1544) Abbreviations: EHNA, erythro-9-(2-hydroxy-3-nonyl)adenine; HARBS, high-affinity rolipram binding site; LARBS, low-affinity rolipram binding site; IBMX, 3-isobutyl-1- methylxanthine; PDE, phosphodiesterase Section: Neuropharmacology 2 JPET Fast Forward. Published on January 24, 2003 as DOI: 10.1124/jpet.102.047407 This article has not been copyedited and formatted.
    [Show full text]
  • Phosphodiesterase-5 Inhibitors and the Heart: Heart: First Published As 10.1136/Heartjnl-2017-312865 on 8 March 2018
    Heart Online First, published on March 8, 2018 as 10.1136/heartjnl-2017-312865 Review Phosphodiesterase-5 inhibitors and the heart: Heart: first published as 10.1136/heartjnl-2017-312865 on 8 March 2018. Downloaded from compound cardioprotection? David Charles Hutchings, Simon George Anderson, Jessica L Caldwell, Andrew W Trafford Unit of Cardiac Physiology, ABSTRACT recently reported that PDE5i use in patients with Division of Cardiovascular Novel cardioprotective agents are needed in both type 2 diabetes (T2DM) and high cardiovascular Sciences, School of Medical risk was associated with reduced mortality.6 The Sciences, Faculty of Biology, heart failure (HF) and myocardial infarction. Increasing Medicine and Health, The evidence from cellular studies and animal models effect was stronger in patients with prior MI and University of Manchester, indicate protective effects of phosphodiesterase-5 was associated with reduced incidence of new MI, Manchester Academic Health (PDE5) inhibitors, drugs usually reserved as treatments of raising the possibility that PDE5is could prevent Science Centre, Manchester, UK erectile dysfunction and pulmonary arterial hypertension. both complications post-MI and future cardio- PDE5 inhibitors have been shown to improve vascular events. Subsequent similar findings were Correspondence to observed in a post-MI cohort showing PDE5i use Dr David Charles Hutchings, contractile function in systolic HF, regress left ventricular Institute of Cardiovascular hypertrophy, reduce myocardial infarct size and suppress was accompanied with reduced mortality and HF 7 Sciences, The University of ischaemia-induced ventricular arrhythmias. Underpinning hospitalisation. Potential for confounding in these Manchester, Manchester, M13 these actions are complex but increasingly understood observational studies is high, however, and data 9NT, UK; david.
    [Show full text]
  • Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Archivio della ricerca- Università di Roma La Sapienza Inflammation, Vol. 39, No. 3, June 2016 (# 2016) DOI: 10.1007/s10753-016-0359-6 ORIGINAL ARTICLE Phosphodiesterase Type 5 Inhibitor Sildenafil Decreases the Proinflammatory Chemokine CXCL10 in Human Cardiomyocytes and in Subjects with Diabetic Cardiomyopathy Luigi Di Luigi,1 Clarissa Corinaldesi,1 Marta Colletti,1 Sabino Scolletta,2 Cristina Antinozzi,1 Gabriella B. Vannelli,3 Elisa Giannetta,4 Daniele Gianfrilli,4 Andrea M. Isidori,4 Silvia Migliaccio,1 Noemi Poerio,5 Maurizio Fraziano,5 Andrea Lenzi,4 and Clara Crescioli1,6 Abstract—T helper 1 (Th1) type cytokines and chemokines are bioactive mediators in inflammation underling several diseases and co-morbid conditions, such as cardiovascular and metabolic disorders. Th1 chemokine CXCL10 participates in heart damage initiation/progression; cardioprotection has been recently associated with sildenafil, a type 5 phosphodiesterase inhibitor. We aimed to evaluate the effect of sildenafil on CXCL10 in inflammatory conditions associated with diabetic cardiomyopathy. We analyzed: CXCL10 gene and protein in human cardiac, endothelial, and immune cells challenged by pro-inflammatory stimuli with and without sildenafil; serum CXCL10 in diabetic subjects at cardiomy- opathy onset, before and after 3 months of treatment with sildenafil vs. placebo. Sildenafil significantly −7 decreased CXCL10 protein secretion (IC50 =2.6×10 ) and gene expression in human cardiomyocytes and significantly decreased circulating CXCL10 in subjects with chemokine basal level ≥ 930 pg/ml, the cut-off value as assessed by ROC analysis. In conclusion, sildenafil could be a pharmacologic tool to control CXCL10-associated inflammation in diabetic cardiomyopathy.
    [Show full text]
  • Effects of Phosphodiesterase Inhibitors on Human Lung Mast Cell and Basophil Function
    British Journal of Pharmacology (1997) 121, 287 ± 295 1997 Stockton Press All rights reserved 0007 ± 1188/97 $12.00 Eects of phosphodiesterase inhibitors on human lung mast cell and basophil function Marie C. Weston, Nicola Anderson & 1Peter T. Peachell Department of Medicine & Pharmacology, University of Sheeld, Royal Hallamshire Hospital (Floor L), Glossop Road, Sheeld S10 2JF 1 The non-hydrolysable cyclic AMP analogue, dibutyryl (Bu2)-cyclic AMP, inhibited the stimulated release of histamine from both basophils and human lung mast cells (HLMC) in a dose-dependent manner. The concentrations required to inhibit histamine release by 50% (IC50) were 0.8 and 0.7 mM in basophils and HLMC, respectively. The cyclic GMP analogue, Bu2-cyclic GMP, was ineective as an inhibitor of histamine release in basophils and HLMC. 2 The non-selective phosphodiesterase (PDE) inhibitors, theophylline and isobutyl-methylxanthine (IBMX) inhibited the IgE-mediated release of histamine from both human basophils and HLMC in a dose-dependent fashion. IBMX and theophylline were more potent inhibitors in basophils than HLMC. IC50 values for the inhibition of histamine release were, 0.05 and 0.2 mM for IBMX and theophylline, respectively, in basophils and 0.25 and 1.2 mM for IBMX and theophylline in HLMC. 3 The PDE 4 inhibitor, rolipram, attenuated the release of both histamine and the generation of sulphopeptidoleukotrienes (sLT) from activated basophils at sub-micromolar concentrations but was ineective at inhibiting the release of histamine and the generation of both sLT and prostaglandin D2 (PGD2) in HLMC. Additional PDE 4 inhibitors, denbufylline, Ro 20-1724, RP 73401 and nitraquazone, were all found to be eective inhibitors of mediator release in basophils but were ineective in HLMC unless high concentrations (1 mM) were employed.
    [Show full text]
  • ED Analogues Analysis
    UPLC-MS/MS for the Screening, Confirmation and Quantification of 32 Drugs illegally added to Herbal/Dietary Supplements for the Enhancement of Male Sexual Performance 1Salman Azimi*, 2Nayan Mistry and 2Michelle Wood 1Drug Quality Control Laboratory, Pharmacy & Drug Control Dept., Supreme Council of Health, PO Box 1919, Doha - Qatar. 2 Figure-5: Photographs of six positive samples. Forty-three suspected Waters Corporation, Atlas Park, Wythenshawe, Manchester, M22 5PP, UK. samples were analyzed in this study; 18 were found to be adulterated with ED drugs. ABSTRACT RESULTS & DISCUSSION The adulteration of herbal/dietary supplements with erectile dysfunction (ED) drugs and their analogues is reported For the purpose of screening , a spectral library for known ED drugs and analogues was prepared. Owing to recent reports Table 2: List of 32 compounds with retention times, and optimised MRM transitions parameters. Table-3: Summary of results for eight adulterated herbal/dietary samples. The screening results, including spectral match worldwide and is an increasing problem[1]. The sale of so-called 100%, ‘all-natural’ products has become a highly of increased availability of ‘all-in-one’/ ‘combination’ herbal products[2], we also added the naturally-occurring substances factors, RT data and final screening status ( = positive or - = negative) are presented, in addition to the quantitative data Retention Precursor Cone Quantifier Qualifier %CV (n=4) from the subsequent confirmatory analysis. profitable business for online pharmacies, however these products can pose a serious threat to consumers owing to the Icariin and yohimbine, the synthetic, dapoxetine (used for premature ejaculation) and testosterone. The library was CE CE Dwell LOQ undisclosed presence of approved/prescription drugs or the unknown safety and toxicity profile of unapproved ED drugs.
    [Show full text]
  • The Single Cyclic Nucleotide-Specific Phosphodiesterase of the Intestinal Parasite Giardia Lamblia Represents a Potential Drug Target
    RESEARCH ARTICLE The single cyclic nucleotide-specific phosphodiesterase of the intestinal parasite Giardia lamblia represents a potential drug target Stefan Kunz1,2*, Vreni Balmer1, Geert Jan Sterk2, Michael P. Pollastri3, Rob Leurs2, Norbert MuÈ ller1, Andrew Hemphill1, Cornelia Spycher1¤ a1111111111 1 Institute of Parasitology, Vetsuisse Faculty, University of Bern, Bern, Switzerland, 2 Division of Medicinal Chemistry, Faculty of Sciences, Amsterdam Institute of Molecules, Medicines and Systems (AIMMS), Vrije a1111111111 Universiteit Amsterdam, Amsterdam, The Netherlands, 3 Department of Chemistry and Chemical Biology, a1111111111 Northeastern University, Boston, Massachusetts, United States of America a1111111111 a1111111111 ¤ Current address: Euresearch, Head Office Bern, Bern, Switzerland * [email protected] Abstract OPEN ACCESS Citation: Kunz S, Balmer V, Sterk GJ, Pollastri MP, Leurs R, MuÈller N, et al. (2017) The single cyclic Background nucleotide-specific phosphodiesterase of the Giardiasis is an intestinal infection correlated with poverty and poor drinking water quality, intestinal parasite Giardia lamblia represents a potential drug target. PLoS Negl Trop Dis 11(9): and treatment options are limited. According to the Center for Disease Control and Preven- e0005891. https://doi.org/10.1371/journal. tion, Giardia infections afflict nearly 33% of people in developing countries, and 2% of the pntd.0005891 adult population in the developed world. This study describes the single cyclic nucleotide- Editor: Aaron R. Jex, University of Melbourne, specific phosphodiesterase (PDE) of G. lamblia and assesses PDE inhibitors as a new gen- AUSTRALIA eration of anti-giardial drugs. Received: December 5, 2016 Accepted: August 21, 2017 Methods Published: September 15, 2017 An extensive search of the Giardia genome database identified a single gene coding for a class I PDE, GlPDE.
    [Show full text]
  • Screening of Phosphodiesterase-5 Inhibitors and Their Analogs in Dietary Supplements by Liquid Chromatography–Hybrid Ion Trap–Time of Flight Mass Spectrometry
    molecules Article Screening of Phosphodiesterase-5 Inhibitors and Their Analogs in Dietary Supplements by Liquid Chromatography–Hybrid Ion Trap–Time of Flight Mass Spectrometry 1,2, 1,3, 4 5 3 Unyong Kim y, Hyun-Deok Cho y, Myung Hee Kang , Joon Hyuk Suh , Han Young Eom , Junghyun Kim 6, Sumin Seo 1, Gunwoo Kim 1, Hye Ryoung Koo 1, Nary Ha 1, Un Tak Song 1 and Sang Beom Han 1,* 1 Department of Pharmaceutical Analysis, College of Pharmacy, Chung-Ang University, 84 Heukseok-ro, Dongjak-gu, Seoul 06974, Korea; [email protected] (U.K.); [email protected] (H.-D.C.); [email protected] (S.S.); [email protected] (G.K.); [email protected] (H.R.K); [email protected] (N.H.); [email protected] (U.T.S.) 2 Biocomplete Co., Ltd., 272 Digital-ro, Guro-gu, Seoul 08389, Korea 3 Bioanalysis and Pharmacokinetics Study Group, Korea Institute of Toxicology, 141 Gajeong-ro, Yuseong-gu, Daejeon 34114, Korea; [email protected] 4 Agro-Livestock and Fishery Products Division, Busan Regional Korea Food and Drug Administration, 222 Geoje-daero, Yunje-gu, Busan 47537, Korea; [email protected] 5 Department of Food Science and Human Nutrition, Citrus Research and Education Center, University of Florida, 700 Experiment Station Rd, Lake Alfred, FL 33850, USA; joonhyuksuh@ufl.edu 6 Forensic Toxicology Division, National Forensic Service, 10 Ipchoon-ro, Wonju, Gangwon-do 26460, Korea; [email protected] * Correspondence: [email protected]; Tel.: +82-2-820-5596 These authors contributed equally to this work. y Received: 22 May 2020; Accepted: 9 June 2020; Published: 12 June 2020 Abstract: An accurate and reliable method based on ion trap–time of flight mass spectrometry (IT–TOF MS) was developed for screening phosphodiesterase-5 inhibitors, including sildenafil, vardenafil, and tadalafil, and their analogs in dietary supplements.
    [Show full text]
  • Signal Transduction Guide
    Signal Transduction Product Guide | 2007 NEW! Selective T-type Ca2+ channel blockers, NNC 55-0396 and Mibefradil ZM 447439 – Novel Aurora Kinase Inhibitor NEW! Antibodies for Cancer Research EGFR-Kinase Selective Inhibitors – BIBX 1382 and BIBU 1361 DRIVING RESEARCH FURTHER Calcium Signaling Agents ...................................2 G Protein Reagents ...........................................12 Cell Cycle and Apoptosis Reagents .....................3 Ion Channel Modulators ...................................13 Cyclic Nucleotide Related Tools ...........................7 Lipid Signaling Agents ......................................17 Cytokine Signaling Agents ..................................9 Nitric Oxide Tools .............................................19 Enzyme Inhibitors/Substrates/Activators ..............9 Protein Kinase Reagents....................................22 Glycobiology Agents .........................................12 Protein Phosphatase Reagents ..........................33 Neurochemicals | Signal Transduction Agents | Peptides | Biochemicals Signal Transduction Product Guide Calcium Signaling Agents ......................................................................................................................2 Calcium Binding Protein Modulators ...................................................................................................2 Calcium ATPase Modulators .................................................................................................................2 Calcium Sensitive Protease
    [Show full text]
  • Penile Injection Therapy | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Penile Injection Therapy This information will help you learn to inject medication into your penis. This is called penile injection therapy. Penile injections can help you achieve an erection if you have erectile dysfunction (ED). Read this resource carefully before starting injection therapy. If you do not follow the instructions in this resource, your doctor or APP may stop prescribing your penile injection medications and supplies. About Penile Injection Therapy The tissue that causes you to get an erection (erectile tissue) is a muscle. Going long periods of time without an erection is unhealthy for erectile tissue and may damage it. We believe having erections keeps erectile tissue healthy. A penile injection helps you have an erection. It works best if it’s given about 5 to 15 minutes before you want an erection. Penile Injection Therapy 1/19 Giving Yourself the Injection Your advanced practice provider (APP) will review the instructions below with you. Generally, the training for the injections takes 2 office visits. Please be aware that each visit may take up to 1 hour, so you should plan your schedule on the day of your appointment. Use this resource to help you the first few times you inject on your own. Do not take the following medications within 18 hours of injecting (before or after): Sildenafil (Viagra®) - 20 mg to 100 mg Vardenafil (Levitra®) - 10 mg to 20 mg Avanafil (Stendra®) - 50 mg to 200 mg If you take tadalafil (Cialis®) 10 mg or 20 mg, do not inject within 72 hours (3 days) of taking the medication.
    [Show full text]
  • Call for Methods
    CALL FOR METHODS Methods for Identification, Determination, or Screening Methods for PDE5 Inhibitors AOAC INTERNATIONAL invites method developers to submit methods for consideration and possible evaluation through the AOAC Official MethodsSM program. Prospective methods may be qualitative, identification methods, and/or screening methods for phosphodiesterase type 5 inhibitors (PDE5 inhibitors) in dietary ingredients and supplements. OBJECTIVE: The objective of this call for methods is to select and evaluate methods that can be used for routine surveillance of dietary ingredients. Acceptable methods must be reliable and reproducible when used by trained analysts in accredited laboratories. Interested method developers should provide a description of their proposed method and data characterizing the analytical performance of the proposed method. For the purpose of this Call-for-Methods, PDE5 inhibitors are defined as avanafil, lodenafil carbonate, mirodenafil, sildenafill, tadalafil, udenafil, or vardenafil; or any of their analogs. Any analytical technique that measures the analytes of interest and meets the method performance requirements specified in the SMPR will be considered. It is acceptable to have a different analytical method for each class of analytes. Applicable SMPRs: • View AOAC 2014.010 – Methods for the Identification of PDE5 Inhibitors • View AOAC SMPR 2014.011 – Methods for the Determination of PDE5 Inhibitors • View AOAC SMPR 2014.012 – Screening Methods for PDE5 Inhibitors Submit Your Method AOAC INTERNATIONAL METHOD SUBMISSION PROCESS: AOAC invites method authors to submit their methods with no fee required. Interested method authors or developers should provide a copy of their proposed method, as well as any available data characterizing the analytical performance and scientific validity of the method in AOAC format.
    [Show full text]